title: Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis.
abstract: Cutaneous T-cell lymphoma (CTCL) is a clonally derived, skin invasive malignancy of CD4+ cells with the phenotype of mature helper T cells. We previously demonstrated that the leukaemic form of CTCL (Sézary), is characterized by prominent immunological defects including depressed cell-mediated immunity. We also demonstrated increased production of T-helper type 2 (Th2) cytokines (IL-4, IL-5) and deficient Th1 cytokines (IL-2 and IFN-gamma) by their peripheral blood mononuclear cells (PBMC) and detected IL-4 and IL-5 mRNA within lesional skin of patients with all stages of CTCL. A marked defect in IL-12 production has also been noted, which may also play a role in depressed cell-mediated immunity. These results suggested that the malignant CD4+ cells were Th2 cells. Thus, the immune aberrations have been attributed to the cytokine abnormalities triggered by the malignant T-cell population. Because CTCL responds to biological response modification, we focused on strategies for reversing the cytokine and immune defects by in vitro testing of novel biological response modifiers. Our results indicate that IFN-alpha potently suppresses the abnormal IL-4 and IL-5 production, that IL-12 can correct the deficient IFN-gamma production and cell-mediated cytotoxicity, and that retinoids can enhance IFN-gamma and IL-12 production. We also studied the in vitro growth characteristics of the malignant CD4+ cells and determined that IL-12 and IFN-alpha significantly suppress growth of these cells. These studies led to a phase I trial of IL-12 to treat CTCL. Also, we have determined that photopheresis produces a high clinical response rate among Sézary syndrome patients. This therapy not only augments functions of monocytes but also induces the malignant T cells to undergo a high rate of apoptosis. We discuss how these therapies might be employed in concert to produce the optimum desired anti-tumour effect.
authors.affiliation: Department of Dermatology, University of Pennsylvania Medical Center, Philadelphia, USA.
authors.forename: A H
authors.initials: AH
authors.lastname: Rook
authors.forename: S L
authors.initials: SL
authors.lastname: Gottlieb
authors.forename: J T
authors.initials: JT
authors.lastname: Wolfe
authors.forename: B R
authors.initials: BR
authors.lastname: Vowels
authors.forename: S S
authors.initials: SS
authors.lastname: Sood
authors.forename: Z
authors.initials: Z
authors.lastname: Niu
authors.forename: S R
authors.initials: SR
authors.lastname: Lessin
authors.forename: F E
authors.initials: FE
authors.lastname: Fox
mesh_terms: D000818:Animals; D003131:Combined Modality Therapy; D016207:Cytokines / Q000627:therapeutic use*; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000209:etiology* / Q000628:therapy; D017893:Photopheresis; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000209:etiology* / Q000628:therapy
chemical_list: D016207:Cytokines; D011994:Recombinant Proteins